Radius Health (RDUS) Shares are Up 2.32%

Radius Health (RDUS) has been under a strong bear grip, hence the stock is down -0.5% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.78% in the past 1 week. The stock has risen by 2.32% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.51% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.32% and the 50-Day Moving Average is 9.45%.The 200 Day SMA reached 32.97% Radius Health, Inc. is up 52.94% in the last 3-month period. Year-to-Date the stock performance stands at -10.43%.


Radius Health (RDUS) : The most positive equity analysts on Radius Health (RDUS) expects the shares to touch $70, whereas, the least positive believes that the stock will trade at $24 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $52.2 with an expected fluctuation of $18.36 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Radius Health (NASDAQ:RDUS): The stock opened at $54.24 and touched an intraday high of $55.42 on Friday. During the day, the stock corrected to an intraday low of $53.78, however, the bulls stepped in and pushed the price higher to close in the green at $55.12 with a gain of 1.16% for the day. The total traded volume for the day was 1,640,749. The stock had closed at $55.12 in the previous trading session.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.